H.C. Wainwright raised the firm’s price target on Krystal Biotech to $221 from $200 and keeps a Buy rating on the shares after Krystal announced “positive” interim safety and efficacy results from Cohorts 3 and Cohorts 4 of the Phase 1 PEARL-1 study of KB301, Jeune Aesthetics’ lead candidate for the treatment of aesthetic skin conditions. Following the date, the firm increased its projected odds of success for KB-301 to 25% from 20%, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
- Krystal Biotech price target raised to $206 from $201 at Evercore ISI
- Krystal Biotech price target raised to $208 from $153 at Chardan
- Krystal Biotech downgraded to Neutral from Buy at Citi
- Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates